Since 2014, SUO has sponsored several awards for the Urology Care Foundation’s Research Scholar program, in order to fund exceptional early-career investigators’ projects in urologic oncology. Each year, we invite the awardees to present an update on their research, and continue to be impressed by the talent and ingenuity of these young urologists.
2022
Laura Bukavina, MD
, The Research Institute of Fox Chase Cancer Center
Mentor: Philip Abbosh, MD, PhD
Investigation of Tumor Infiltrating Lymphocytes: An Immunoscore Prediction Model
Sponsor: Society for Urologic Oncology
2022
Karla Parra, PhD
, UT Southwestern Medical Center
Mentor: Ganesh Raj, MD, PhD
Therapeutic Targeting of Prostate Cancer Metastases
2021
Deborah Kaye, MD
, Duke University
Mentors: Peter Ubel, MD; Sharron Docherty, PhD; Kathryn Pollak, PhD; Charles Scales, MD, MPH; and Daniel George, MD
DECREASING THE FINANCIAL BURDEN FOR PATIENTS WITH ADVANCED PROSTATE CANCER BY UNDERSTANDING PROVIDER DECISION-MAKING
2021
Richard Matulewicz, MD
, Memorial Sloan-Kettering Cancer Center
Mentor: Danil Makarov, MD, MHS
EVALUATION AND VALIDATION OF THE NEW AUA MICROHEMATURIA GUIDELINES
2021
Chen Qian, PhD
, Cedars-Sinai Medical Center
Mentors: Michael Freeman, PhD; Beatrice Knudsen, MD, PhD; and Lily Wu, MD, PhD
TARGETING ONECUT2: DIFFERENTIAL ROUTES TO METASTASIS IN MCRPC
2021
Udit Singhal, MD
, University of Michigan
Mentors: Todd Morgan, MD and Daniel Spratt, MD
COMPREHENSIVE ASSESSMENT OF A NOVEL CLINICAL TRIAL PLATFORM IN UROLOGY
2020
Pauline Filippou, MD
, University of Washington
Mentor: John Gore, MD
Characterizing end-of-life care in bladder cancer patients
2020
Chen Qian, PhD
, Cedars-Sinai Medical Center
Mentors: Michael Freeman, PhD; Beatrice Knudsen, MD, PhD; and Lily Wu, MD, PhD
Targeting ONECUT2: Differential routes to metastasis in mCRPC
2020
Andrew Tracy, MD
, Memorial Sloan Kettering Cancer Center
Mentors: Jonathan Coleman, MD & Kwanghee Kim, PhD
Genomic characterization of the tumor microenvironment in upper tract urothelial carcinoma
2019
Xiaosong Meng, MD, PhD
, UT Southwestern Medical Center
Mentors: Vitaly Margulis, MD; Hans Hammers, MD, PhD; Xiankai Sun, PhD
DETECTION OF INVASIVE RENAL CELL CARCINOMA WITH TARGETED MOLECULAR IMAGING
2018
Shawn Dason, MD
, Memorial Sloan Kettering Cancer Center
Phylogenic Analysis of Chemotherapy-Resistant Urothelial Carcinoma of the Bladder
2018
Brandon Manley, MD
, H. Lee Moffitt Cancer Center and Research Institute
Mentor: Anthony Magliocco, MD
Employing Multiparametric Profiling to Characterize Immunotherapy Responders in Clear Cell Renal Cell Carcinoma
2018
Karen Wheeler, MD, PhD
, University of Texas Health Science Center at San Antonio
Mentor: Robert Svatek, MD
Impact of Surgery on Response to Cancer Immunology
2017
William B. Tabayoyong, MD, PhD, MS/MSc
, University of Texas, MD Anderson Cancer Center
Mentor: Ashish Kamat, MD, MBBS
Phenotypic and Functional Characterization of T cells in bladder Cancer Patients Treated with Pembrolizumab, an Anti-PD1 Antibody, Prior to Cystectomy
2016
Suk Hyung Lee, PhD
, Columbia University Medical Center
Mentor: Michael Shen, PhD
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
2016
Simpa S. Salami, MD, MPH
, University of Michigan Medical School
Mentors: Ganesh Palapattu, MD; Scott Tomlins, MD, PhD and Leonard Marks, MD
Molecular Profiling of Serial Targeted Biopsy Tissue to Predict Progression of Low to High Grade Prostate Cancer
2016
Geoff Sonn, MD
, Stanford University
Mentors: Richard Zare, PhD and James Brooks, MD
Diagnosis of Prostate Cancer by Desorption Electrospray Ionization Mass Spectrometric Imaging of Small Metabolites and Lipids
2015
Aditya Bagrodia, MD
, Memorial Sloan Kettering Cancer Center
Mentors: David B. Solit, MD and Jonathan A. Coleman, MD
The Prognostic and Therapeutic Value of Genomic Alterations and PI3K/AKT/mTOR Aberrations in Upper Tract Urothelial Carcinoma
2015
Anobel Y. Odisho, MD, MPH
, University of Washington School of Medicine
Mentor: John L. Gore, MD
The Impact of Clinical and Demographic Factors on Risk-Adjusted Outcomes for Urologic Cancer Surgery